Aclaris Therapeutics reported QQ1 2025 results that underscore the company’s status as a clinical-stage biopharmaceutical with limited near-term revenue and meaningful operating losses driven by R&D spend. Revenue for the quarter was $1.455 million, producing a gross profit of $0.949 million and a gross margin of 65.2%. The company posted an operating loss of $18.084 million and a net loss of $15.085 million, translating to an EPS of -$0.12. The quarter featured heavy R&D investment ($11.584 million) and ongoing SG&A expenses ($6.139 million), resulting in a negative EBITDA of $18.084 million. The cash burn was evident in cash flow from operations of −$13.057 million and free cash flow of −$13.100 million, with ending cash and equivalents of $30.357 million. This places near-term liquidity in a favorable position relative to burn, but the absence of product revenue keeps the business highly sensitive to funding; management commentary and strategic focus remain anchored in advancing the pipeline and de-risking key programs.
From a balance sheet perspective, the company reported total assets of $198.094 million and total liabilities of $54.028 million, yielding shareholders’ equity of $144.066 million. The net debt position is negative $30.357 million, reflecting a net cash posture that provides runway to fund ongoing clinical development. Key liquidity metrics appear solid with a current ratio of ~5.06, indicating ample short-term liquidity given current liabilities. In the context of the broader biotech sector, Aclaris trades with a substantial price-to-sales multiple given minimal revenue, underscoring investor expectations for meaningful pipeline-related value realization over the medium term.